Share
))
HBO and The Ringer's Bill Simmons hosts the most downloaded sports podcast of all time, with a rotating crew of celebrities, athletes, and media staples, as well as mainstays like Cousin Sal, Joe House, and a slew of other friends and family members who always happen to be suspiciously available.
…
continue reading
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on December 17, 2025 04:10 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 524642999 series 3693262
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Host: Ryan Quigley
Guest: Kathrin M. Bernt, MD
Guest: Rushabh Mehta, BS
Guest: Fatemeh Alikarami
New data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition reveals how chemotherapy and immunotherapy may drive the emergence of CD-19–negative, myeloid-like subclones in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Mr. Ryan Quigley sits down with Dr. Kathrin Bernt, Dr. Fatemah Alikarami, and Mr. Rushabh Mehta to discuss how their findings could impact minimal residual disease detection, therapy resistance, and future risk stratification strategies. Dr. Bernt is a pediatric oncologist and an Associate Professor of Pediatrics at the Children’s Hospital of Philadelphia. Dr. Alikarami is a Research Associate Scientist at the Children’s Hospital of Philadelphia. Mr. Mehta is a PhD candidate in cell and molecular biology at the University of Pennsylvania.
…
continue reading
Guest: Kathrin M. Bernt, MD
Guest: Rushabh Mehta, BS
Guest: Fatemeh Alikarami
New data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition reveals how chemotherapy and immunotherapy may drive the emergence of CD-19–negative, myeloid-like subclones in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Mr. Ryan Quigley sits down with Dr. Kathrin Bernt, Dr. Fatemah Alikarami, and Mr. Rushabh Mehta to discuss how their findings could impact minimal residual disease detection, therapy resistance, and future risk stratification strategies. Dr. Bernt is a pediatric oncologist and an Associate Professor of Pediatrics at the Children’s Hospital of Philadelphia. Dr. Alikarami is a Research Associate Scientist at the Children’s Hospital of Philadelphia. Mr. Mehta is a PhD candidate in cell and molecular biology at the University of Pennsylvania.
187 episodes
